clinical trial · NCT06663358
A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients
Chiesi Farmaceutici S.p.A.·—·recruiting·n = 100
Fabry DiseasePegunigalsidase-alfa
brief summary
A multi-centre, multi-country, observational, non-interventional, retrospective and prospective (hybrid) study among Fabry disease participants treated with pegunigalsidase alfa (Elfabrio®) in routine clinical care.
started
Nov 6, 2024
primary completion
Nov 1, 2029
completion
Nov 1, 2029
last updated
Nov 14, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol